4.06
0.03 (0.74%)
Previous Close | 4.03 |
Open | 4.07 |
Volume | 1,062,397 |
Avg. Volume (3M) | 1,115,659 |
Market Cap | 276,306,656 |
Price / Earnings (Forward) | 3.62 |
Price / Book | 8.44 |
52 Weeks Range | |
Earnings Date | 12 Nov 2025 |
Diluted EPS (TTM) | -3.04 |
Current Ratio (MRQ) | 1.16 |
Operating Cash Flow (TTM) | -142.86 M |
Levered Free Cash Flow (TTM) | -102.50 M |
Return on Assets (TTM) | -30.70% |
Market Trend
Short Term | Medium Term | ||
Industry | Biotechnology (US) | Mixed | Bearish |
Biotechnology (Global) | Mixed | Bearish | |
Stock | Omeros Corporation | Bullish | Bullish |
AIStockmoo Score
Analyst Consensus | 3.5 |
Insider Activity | NA |
Price Volatility | -2.0 |
Technical Moving Averages | 0.0 |
Technical Oscillators | -0.5 |
Average | 0.25 |
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy. |
|
Sector | Healthcare |
Industry | Biotechnology |
Investment Style | Small Value |
% Held by Insiders | 4.40% |
% Held by Institutions | 47.30% |
Ownership
Name | Date | Shares Held |
---|---|---|
Deepcurrents Investment Group Llc | 30 Jun 2025 | 528,129 |
52 Weeks Range | ||
Median | 36.00 (786.70%) | |
Total | 1 Buy |
Firm | Date | Target Price | Call | Price @ Call |
---|---|---|---|---|
D. Boral Capital | 03 Sep 2025 | 36.00 (786.70%) | Buy | 4.18 |
15 Aug 2025 | 36.00 (786.70%) | Buy | 4.41 |
No data within this time range.
Date | Type | Details |
---|---|---|
02 Sep 2025 | Announcement | Omeros Announces Publication Highlighting Survival Outcomes in TA-TMA Patients Treated with Narsoplimab Under Its Global Expanded Access Program |
14 Aug 2025 | Announcement | Omeros Corporation Reports Second Quarter 2025 Financial Results |
11 Aug 2025 | Announcement | Omeros Corporation to Announce Second Quarter Financial Results on August 14, 2025 |
31 Jul 2025 | Announcement | D. Boral Capital Acted as Exclusive Placement Agent to Omeros Corporation (Nasdaq: OMER) in Connection with its $22,000,000 Registered Direct Offering |
25 Jul 2025 | Announcement | Omeros Corporation Announces Pricing of $22 Million Registered Direct Offering |
27 Jun 2025 | Announcement | Omeros Submits Narsoplimab Marketing Authorization Application to the European Medicines Agency for the Treatment of TA-TMA |
24 Jun 2025 | Announcement | Omeros Announces Webcast Details for Annual Meeting of Shareholders |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2025 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |